TY - JOUR T1 - Association of the Liver and Plasma Lipidomes with the Histological Stage of Alcohol-Related Liver Disease JF - medRxiv DO - 10.1101/2021.07.13.21260429 SP - 2021.07.13.21260429 AU - Maja Thiele AU - Tommi Suvitaival AU - Kajetan Trošt AU - Min Kim AU - Andressa de Zewadzki AU - Maria Kjaergaard AU - Ditlev Nytoft Rasmussen AU - Katrine Prier Lindvig AU - Mads Israelsen AU - Sönke Detlefsen AU - Peter Andersen AU - Helene Bæk Juel AU - Trine Nielsen AU - Stella Georgiou AU - Vicky Filippa AU - Michael Kuhn AU - Suguru Nishijima AU - Lucas Moitinho-Silva AU - Peter Rossing AU - Jonel Trebicka AU - Ema Anastasiadou AU - Peer Bork AU - Torben Hansen AU - Cristina Legido Quigley AU - Aleksander Krag AU - on behalf of the MicrobLiver and GALAXY Consortia Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/16/2021.07.13.21260429.abstract N2 - Background and aims Alcohol disturbs hepatic lipid synthesis and transport, but the role of lipid dysfunction in the severity of alcohol-related liver disease (ALD) is unclear. We therefore characterised the liver and plasma lipidome in a biopsy-controlled cohort of patients with early ALD.Methods We performed ultra-high-performance liquid chromatography quadrupole time-of-flight mass spectrometry for lipidomics of the liver and plasma from 315 patients, and of plasma from 51 healthy controls matched for age, gender and BMI. We correlated lipid levels with histological fibrosis, inflammation and steatosis, after correction for multiple testing and adjustment for age, gender, statin use, BMI, HbA1c, HOMA-IR, and ongoing drinking. Moreover, we investigated the mechanism of dysregulated sphingolipid metabolism by whole-blood transcriptomics and qPCR sequencing of miRNA.Results We detected 198 lipids in the liver and 236 lipids in the circulation from 18 lipid classes. Nearly all ceramides, sphingomyelins and lyso-phosphocholines in plasma decreased as fibrosis progressed. This was paralleled by a comparable decrease in the liver. Circulating and liver sphingomyelins were also inversely associated with hepatic inflammation. The lipidomic signature of healthy controls was only comparable to ALD patients with no fibrosis. Three circulating miRNA, highly involved in sphingomyelin metabolism, were dysregulated together with the mRNA expression of enzymes in the sphingomyelin degradation pathway. Mendelian randomization in Finnish and UK population biobanks externally validated our findings, suggesting a causal relationship between genetic disposition to ALD and low sphingolipid levels.Conclusions Liver fibrosis severity in alcohol-related liver disease is characterized by selective lipid depletion in blood and liver, indicating profound effects of progressive disease on the bioactive sphingolipids, already from early stages of fibrosis.HighlightsThe lipidome in the liver and circulation in alcohol-related liver disease (ALD)Sphingolipid, phospholipid and triacylglycerol levels were lowered in fibrosisExpression and regulation of genes in the sphingolipid pathway were affectedALD has a causal link to lowered sphingomyelin levels in bloodLay summary Alcohol causes a dysfunctional fat metabolism in the liver. In this study, we detected 198 different types of lipids in the liver and 236 in the blood stream of patients with different severity of alcohol-related liver disease. We found that patients with more severe scarring (fibrosis) of the liver, and more severe liver inflammation, had lower levels of sphingolipids both in the circulation and the liver. Sphingolipids regulate cell survival and inflammation, so they may be involved in the mechanism of progressive alcohol-related liver disease.Competing Interest StatementJT has received speaking and/or consulting fees from Gore, Bayer, Alexion, MSD, Gilead, Intercept, Norgine, Grifols, Versantis, and Martin Pharmaceutical. PR has received honoraria to Steno Diabetes Center Copenhagen from teaching and consultancy for Astellas, Astra Zeneca, Boehringer Ingelheim, Bayer, MSD, Gilead, Novo Nordisk, Sanofi, VIfor and Eli Lilly.Funding StatementThis project received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement number 668031 to the GALAXY consortium, and from the Challenge grant number NNF15OC0016692 from the Novo Nordisk Foundation to the MicrobLiver consortium. PB and MKu were supported by EMBL.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The studies received approval by the Danish data protection agency (13/8204, 16/3492) and the ethics committee for Region of Southern Denmark (ethical ID S-20120071, S-20160021, S-20170087, S-20160006G).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are available by contact to open{at}rsyd.dk , after approval from the Danish Data Protection Agency.ALDalcohol-related liver diseaseANCOVAanalysis of covarianceBMIbody mass indexCerceramidesDGdiacylglycerolsFAfree fatty acidsHbA1Cglycated hemoglobinHexCerhexocyl-ceramidesHOMA-IRhomeostasis model assessment for insulin resistanceLacCerlactocyl-ceramidesLPClyso-phosphocholinesLPC-O/Palkyl or alkenyl ether lyso-phosphocholinesLPElyso-phosphatidylethanolaminesNAFLDnon-alcoholic fatty liver diseasePCphosphocholinesPC-O/Palkyl-acyl phosphocholinesPEphosphatidylethanolaminesPE-O/Palkyl or alkenyl ether phosphatidylethanolaminesPGphosphatidylglycerolsPIphosphatidylinositolsPSphosphatidylserinesS1Psphingosine-1-phosphateSHexCersulfatide hexocyl-ceramidesSMsphingomyelinsTGtriacylglycerols ER -